Background Osimertinib is one of the first-line treatments for advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. However, the occurrence rate of osimertinib-induced interstitial lung disease (ILD) is particularly high in Japanese patients and little information on subsequent cancer treatment options after recovery from osimertinib-induced ILD is currently available. Thus, this study aims to determine the safety and efficacy of afatinib for the treatment of NSCLC following osimertinib-induced ILD. Methods We retrospectively investigated the clinical courses of all NSCLC patients with EGFR mutations at our facility between August 2018 and September 2019, who received osimertinib as first-line treatment and were subsequently treated with afatinib after developing osimertinib-induced ILD. Results Forty-two patients received osimertinib treatment at our facility during the study period, and four patients received afatinib after developing osimertinib-induced ILD. All events of ILD improved either spontaneously or with steroid therapy before the initiation of afatinib. For the four patients who were retrospectively reviewed, the overall response rate to afatinib therapy was 75%, and the disease control rate was 100%. During the study period, no ILD recurrence was observed in any of the four patients. Conclusions According to our study findings, afatinib treatment after osimertinib-induced ILD is considered safe and effective and it can be used as one of the treatment options for NSCLC following osimertinib-induced ILD.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Mok TS, Wu Y-L, Ahn M-J et al (2017) Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 376:629–640
Soria JC, Ohe Y, Vansteenkiste J et al (2018) Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378:113–125
Ramalingam SS, Vansteenkiste J, Planchard D et al (2020) Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 382:41–50
Ohe Y, Imamura F, Nogami N et al (2019) Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset. Jpn J Clin Oncol 49:29–36
Kato T, Yoshioka H, Okamoto I et al (2015) Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3. Cancer Sci 106:1202–1211
Camus P, Fanton A, Bonniaud P et al (2004) Interstitial lung disease induced by drugs and radiation. Respiration 71:301–326
Itano J, Higo H, Ohashi K et al (2020) Successful re-administration of osimertinib in osimertinib-induced interstitial lung disease with an organizing pneumonia pattern: a case report and literature review. Intern Med 59:823–828
Ando M, Okamoto I, Yamamoto N et al (2006) Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 24:2549–2556
Gemma A, Kudoh S, Ando M et al (2014) Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer. Cancer Sci 105:1584–1590
Miyauchi E, Ichinose M, Inoue A (2017) Successful osimertinib rechallenge in a patient with T790M-mutant non-small cell lung cancer after osimertinib-induced interstitial lung disease. J Thorac Oncol 12:e59–e61
Nagasaka M, Gadgeel SM (2018) Retreatment with osimertinib following pneumonitis. Clin Lung Cancer 19:e53–e55
Kiriu T, Tamura D, Tachihara M et al (2018) Successful osimertinib rechallenge with steroid therapy after osimertinib-induced interstitial lung disease. Intern Med 57:91–95
Satoh S, Shiroyama T, Tamiya M et al (2017) Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma. Respir Med Case Rep 23:68–70
Schoenfeld AJ, Arbour KC, Rizvi H et al (2019) Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Ann Oncol 30:839–844
Koyama S, Omura T, Yonezawa A et al (2015) Gefitinib and erlotinib lead to phosphorylation of eukaryotic initiation factor 2 alpha independent of epidermal growth factor receptor in A549 cells. PLoS One 10:e0136176
Lee H, Lee HY, Sun JM et al (2018) Transient asymptomatic pulmonary opacities during osimertinib treatment and its clinical implication. J Thorac Oncol 13:1106–1112
Noonan SA, Sachs PB, Camidge DR (2016) Transient asymptomatic pulmonary opacities occurring during osimertinib treatment. J Thorac Oncol 11:2253–2258
Yokoyama T, Yoshioka H, Fujimoto D et al (2019) A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402). Lung Cancer 135:175–180
Kashiwabara K, Semba H, Fujii S et al (2016) Tolerability and efficacy of afatinib at a low starting dosage in 10 elderly or low performance status patients with advanced refractory non-small-cell lung cancer. Respir Investig 54:468–472
Schuler M, Wu YL, Hirsh V et al (2016) First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J Thorac Oncol 11:380–390
Paz-Ares L, Tan EH, O’Byrne K et al (2017) Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol 28:270–277
Inoue A, Kobayashi K, Usui K et al (2009) First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 27:1394–1400
Conflict of interest
The authors declare that they have no conflict of interest.
Institutional review board (IRB) approval for this study was obtained from the Medical Research Ethics Committee of Osaka Habikino Medical Center. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was waived by the IRB because of the retrospective nature of this study.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Nasu, S., Suzuki, H., Shiroyama, T. et al. Safety and efficacy of afatinib for the treatment of non-small-cell lung cancer following osimertinib-induced interstitial lung disease: A retrospective study. Invest New Drugs (2020). https://doi.org/10.1007/s10637-020-00963-w
- Drug-induced interstitial lung disease
- Epidermal growth factor receptor mutation